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Publicly funded cancer medicines listed on the New Zealand Pharmaceutical Schedule were compared
with those listed on the Australian Pharmaceutical Beneﬁts Scheme. To quantify the health gains offered
by the cancer medicines funded in Australia but not in New Zealand, clinical trial data reporting median
progression-free survival (PFS) and overall survival (OS) were sought. The differences in the median PFS
and OS for the unfunded medicines, relative to the comparator medicine funded in NZ, were then
assessed against the American Society of Clinical Oncology Cancer Research Committee (ASCO-CRC)
recommended targets for clinically meaningful health gains. Our analysis conﬁrms that, whilst New
Zealand funds fewer cancer medicines than Australia, most of the additional medicines funded in
Australia do not deliver clinically meaningful health gains as deﬁned by the ASCO-CRC guidance. This
suggests that New Zealand is not missing substantive opportunities for improvements to New Zealand’s
cancer survival rates through additional medicines funding. A policy of funding more new cancer
medicines in order to achieve numerical parity with Australia or other countries would not result in
substantive health improvement and would cost signiﬁcantly more, and investing the millions of dollars
needed to achieve funding parity with other countries would not represent good value for money in terms of
delivering the best health outcomes for all New Zealanders, rather selective funding of new medicines that
demonstrate clear clinical beneﬁt and that are cost-effective and affordable is the sensible approach.
& 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The Pharmaceutical Management Agency, or PHARMAC, is the
government agency that decides which medicines are publicly
funded in New Zealand. PHARMAC is charged with ensuring that
New Zealand obtains the best health outcomes from funded
pharmaceuticals from within the amount of funding providedInc. This is an open access article u
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w Zealand.
(S. Crausaz)[1]. It is therefore interested in understanding whether its funding
decisions enable access to the right mix of medicines to achieve
that goal.
Pharmaceutical industry–funded reports frequently provide
comparisons of medicines funded by various countries national
healthcare systems [2–5], with some painting a picture of funded
medicines access in New Zealand being low and slow. The authors
of such reports usually draw their conclusions by counting the
number of medicines funded in each country, or the time taken to
fund them from regulatory approval, but rarely do they explore the
value of the unfunded medicines in terms of their health beneﬁts,
risks, affordability, and likely impact on population health out-
comes, including consideration of opportunity cost (alternative
medicines or health services that the same funding could pur-
chase). Some reports suggest that access to fewer cancer medi-
cines in New Zealand results in worse population health outcomes.
A recent example written by Medicines New Zealand [6], the New
Zealand Pharmaceutical Industry association, argued that the
observed lower cancer survival rate in New Zealand comparednder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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cancer medicines between the two countries. We were interested
in exploring this further by asking the question whether achieving
numerical parity with Australia for funded cancer medicines
would make a clinically meaningful impact on cancer outcomes
for New Zealand.
Health beneﬁts offered by new cancer medicines may range
from marginal (progression-free survival [PFS] improvement of
only a few weeks or less, with no effects on overall survival [OS])
to substantial and clinically meaningful (improved long-term OS of
several months or more).
Most new cancer medicines are developed and marketed on
the basis of clinical trial data showing statistically signiﬁcant
improvements in length of life or time to disease progression over
placebo or a comparator treatment. However, in many cases, the
absolute health gains for patients from these medicines are small,
coupled with prices that are increasingly disproportionate to the
small beneﬁts provided [8–10]. A recent analysis by Howard and
colleagues showed that the average launch price of new cancer
medicines, adjusted for inﬂation and survival beneﬁts, had
increased 10% annually over the last decade, up US $8,500 each
year [11]. This price inﬂation far outweighs the survival beneﬁts
offered by these new medicines with the estimated price per year
of life in 1995 being $54,100, rising to $139,100 in 2005 and
$207,000 by 2013. One example of disproportional pricing is in
colorectal cancer; although new medicines have indeed improved
outcomes for patients with metastatic disease, nearly doubling the
median survival time from 12 to 21 months, this gain has come at a
340-fold increase in cost [12].
The rising cost of cancer medicines, and the impact on health-
care systems and patients, has been debated in many countries
including the United States. Some US hematologists and oncolo-
gists have strongly asserted that the health gains offered for some
new cancer medicines do not justify their premium costs, leading
to decisions not to prescribe them [13–16] and recommendations
to consider the so-called “ﬁnancial toxicity” new medicines place
on patients [17]. In countries with universal publicly funded
healthcare the rising cost of medicines threatens the sustainability
of these systems, risking budget overspend and diversion of
funding away from other, more cost-effective health interventions
[18,19].
In response to this increasing trend of higher pricing and more
marginal health gains, the American Society of Clinical Oncology
(ASCO) and the European Society for Medical Oncology (ESMO)
have developed tools to help prescribers determine the value of
the health beneﬁts offered by new medicines [20,21]. The ASCO
Cancer Research Committee (ASCO-CRC) also recently published
recommended targets for clinically meaningful PFS and OS gains
for new cancer treatments [22]. These targets were developed
with broad input and diverse points of view by working groups
comprising pancreas, breast, lung, and colon cancer experts
including clinical investigators, biostatisticians, patient advocates,
US Food and Drug Administration (FDA) oncologists, and industry
oncologists.
PHARMAC uses its Factors for Consideration [23], previously
Decision Criteria [24], which include, amongst other things, con-
sideration of health need, beneﬁts and risks, value for money and
affordability to determine the relative importance (rank) of its
various funding options and inform its funding decisions. Like
many other public medicines funding bodies internationally,
PHARMAC uses cost utility analyses (CUAs) to estimate the
value-for-money, or cost effectiveness, of new medicines in terms
of cost per quality-adjusted life-year (QALY). However, such
analyses are complex to perform and can be highly imprecise, or
biased, where the evidence base from clinical trials is limited or
confounded, for example by cross-over of patients from thecomparator arm to the intervention arm. Thus, relying on cost-
effectiveness analyses alone to drive funding decisions through use
of explicit cost-effectiveness thresholds as some public funding
bodies do, is problematic. PHARMAC uses cost-effectiveness anal-
yses to provide information on the relative value of one medicine
funding choice compared with other funding choices. When used
this way to deliver information regarding relative value, or rank,
rather than trying to derive an absolute value, the impact of poor
quality or biased clinical trial evidence is less critical. Using cost-
effectiveness this way is also less resource intensive, in many cases
simple models can be used with the impact of various inputs
tested through sensitivity analyses, thus resource can be focussed
on the few key inputs that impact the model outputs, and other
inputs that don’t substantially change the output can be largely
ignored.
However, when used in isolation cost-effectiveness analyses,
whichever way they are used, do not address the issue of
opportunity cost and affordability of new medicines. PHARMAC’s
national ﬁxed budget for medicines ensures that it fully considers
the opportunity cost and affordability of new medicines when
making its funding decisions. PHARMAC ranks new medicines as
options for investment taking into account its Factors for Consid-
eration, a process that ensures that funding for the most valuable
and affordable medicines is progressed. However, having a ﬁxed
budget means that not all new medicines can be funded as health
demands exceed ability to pay. Health gains may need to be
foregone in some disease settings in order for PHARMAC to deliver
on its objective of providing the best health outcomes from
medicines for all New Zealanders from the available funding.
To describe the population health gains foregone from
unfunded cancer medicines, PHARMAC commissioned research
comparing funded cancer medicines in New Zealand and Australia.
To understand whether any funding gap would likely be substan-
tively contributing to New Zealanders’ poorer cancer outcomes
compared with Australia, we considered whether the non-funded
cancer medicines would deliver clinically meaningful health gains
for patients or not. Australia was selected as the comparator
because of cultural proximity, readily available medicines funding
information, and its reportedly superior cancer survival rates
compared with New Zealand [7]. For reasons of geographic
proximity, along with population ties between the two countries,
it is also often quoted in New Zealand as the most obvious
comparator country.2. Method
The Australian Pharmaceutical Beneﬁts Scheme (PBS) [25] and
the New Zealand Pharmaceutical Schedule [26] were queried to
identify publicly funded cancer medicines as of April 30, 2016.
Analyses were performed to identify the medicines and their
funded indications in cancer that were the same in both countries
as well as those funded in one country and not the other.
To describe the health gain expected from the medicines
funded only in Australia and not in New Zealand, we sourced
clinical trial data reporting PFS and OS for each of the Australian
funded indications for these medicines from the Australian Prod-
uct Information (PI) document. We selected PFS and OS as the
most appropriate measure of health gain as these are standard,
internationally recognised cancer endpoints widely used in com-
parative clinical trials to quantify health beneﬁts.
PFS is deﬁned as the time from randomisation (ie, when a
patient is enrolled into a clinical trial) until cancer disease
progression or death. OS is deﬁned as the time from randomisation
until death from any cause [27]. The Australian PI document
was chosen as the primary source document for PFS and OS data.
Table 1
Summary of ASCO-CRC recommended targets for meaningful clinical trial goals.
Cancer type Patient population Improvement in PFS that would be
considered clinically meaningful (mo)
Improvement in OS that would be
considered clinically meaningful (mo)
Breast cancer Metastatic triple negative, previously untreated for metastatic disease 4 4.5–6
Colon cancer Disease progression with all prior therapies (or not a candidate
for standard second or third-line options)
3–5 3–5
Lung cancer Non-squamous cell carcinoma 4 3.25–4
Squamous cell carcinoma 3 2.5–3
Pancreatic cancer Fit patients (eligible for FOLFIRINOX) 4–5 4–5
Less ﬁt patients (eligible for Gemcitabine or
gemcitabine / nab-paclitaxel)
3–4 3–4
Lower and Upper range across cancer types 3–5 2.5–6
Source: adapted from Ellis et al, 2014 [22]
Both 
Countries NZAus
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ness of the medicine and summarises the primary data used by the
pharmaceutical company to gain regulatory approval. It contains
information about the design and results of clinical trials as well as
the indications for use of the medicine, and forms the basis of the
therapeutic claims that can be made for the medicine by the
pharmaceutical company. We searched the Australian Register of
Therapeutic Goods [28] to identify relevant PI documents for each
medicine. We also conducted an online search for relevant clinical
trial data reported in peer-reviewed academic journals; where PI
and journal articles reported different results for the same trial we
used the PI as the primary data source.
We focused on comparative clinical trials that reported median
PFS and OS gains for the new medicine compared with a New
Zealand–funded alternative and calculated the median gain for
each medicine. In some cases, the clinical trial data in the PI
reported time to progression (TTP) data instead of PFS. In such
cases, we used TTP as a substitute for PFS because both measures
focus on time to disease progression, with TTP only differing from
PFS in that it does not include deaths from non-cancer causes.
Where multiple studies were reported with different indications
or comparators, we selected the study that best reﬂected the
Australian-funded indication and the relevant funded comparator
in New Zealand. Where more than one such study was reported
we used data from the study reporting the greatest gains for the
Australian-funded treatment. Where no evidence was available
from clinical trials with an appropriate New Zealand–funded
comparator, we undertook an adjusted indirect comparison with
common comparator using the Bucher method [29] to estimate
the median gain relative to the New Zealand–funded comparator.
Our benchmarks for determining whether the medicines pro-
vided clinically meaningful health gains for patients were drawn
from the recommendations of the ACSO-CRC [22]. Table 1 summa-
rizes these recommendations. The recommended incremental
gains deﬁned as clinically meaningful across the cancer types
considered ranged from the lowest to highest targets of 3.0 to
5.0 months, respectively, for PFS, and 2.5 to 6.0 months for OS.
We then assessed the PFS and OS gains for the cancer
medicines we identiﬁed as being funded in Australia, but not
New Zealand, against these targets to determine which would
deliver clinically meaningful gains for patients.89 1335
Fig. 1. Number of cancer medicines funded in Australia and New Zealand at April
30, 2016. Source: Australian Pharmaceutical Beneﬁts Scheme and the New Zealand
Pharmaceutical Schedule accessed April 30, 2016.3. Results
We identiﬁed 124 cancer medicines listed on the Australian PBS
and 102 listed on New Zealand’s Pharmaceutical Schedule at the
analysis date of April 30, 2016. Eighty-nine were funded in both
countries, with 35 funded exclusively in Australia and 13 funded
exclusively in New Zealand, as shown in Fig. 1.Fig. 2 outlines how the ﬁnal set of cancer medicines for our
analysis was derived. Clinical trial data reporting median PFS or OS
gains relative to comparator treatments were available for 26 of
the 35 cancer medicines funded in Australia but not in New
Zealand. Nine medicines were excluded because no comparative
clinical trial data reporting median PFS or OS gains were reported
(fotemustine, combination goserelin with bicalutamide, niluta-
mide, degarelix, idarubicin capsules, ponatinib, brentuximab, tras-
tuzumab subcutaneous, and rituximab subcutaneous).
Table 2 summarizes the ﬁnal set of 26 cancer medicines
analysed, their Australian-funded indication(s) and describes the
source clinical trial for the PFS and OS data used and the New
Zealand–funded comparator treatment. Nineteen medicines had a
single indication funded in Australia and seven were funded for
two indications each. For two medicines, OS data were available
but PFS data were not reported, and for four medicines PFS was
available but OS was not reported. For three medicines (axitinib,
trametinib, and pembrolizumab), clinical trial data with a New
Zealand–funded comparator were not available, necessitating
adjusted indirect comparison analysis being performed (compara-
tors being placebo for axitinib, dacarbazine for trametinib, and
dacarbazine for pembrolizumab).
Table 3 presents the clinical trial PFS and OS outcome data
reported for each of the 26 Australian-funded medicines, for each
of their 33 funded indications, together with PFS and OS outcome
data of their New Zealand–funded comparator treatments. Table 3
also shows the calculated PFS and OS gains relative to the
comparator treatment for each medicine and the median PFS
and OS gain across the group of medicines.
Fig. 3 presents the reported median PFS health gains for each of
the Australian-funded cancer medicines relative to the New
Fig. 2. Flow chart for deriving set of cancer medicines for foregone health gain analysis.
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largest on the left to those that offer PFS losses on the right.
Fig. 3 also illustrates the relationship between the reported PFS
gains and the ASCO-CRC working groups’ clinically meaningful PFS
targets. Green bars represent the gains that met or exceeded the
ASCO-CRC upper target for clinically meaningful PFS health gain
(PFS gain of 5 months or more), orange bars represent gains that
fell below the upper target but met or exceeded the lower target
(Z3 months to o5 months), and red bars those that fell below
the lower target (o3 months).The thresholds for clinically mean-
ingful gains are also illustrated represented by horizontal lines.
Similarly, Fig. 4 presents the median OS gains relative to the
New Zealand–funded comparator and their relationship with the
ASCO-CRC targets for lower and upper clinically meaningful OS
gain (green Z6 months; orange Z2.5 months to o6 months; red
o2.5 months).
The median PFS and OS gains across all 26 cancer medicines
were 2.2 and 2.6 months, respectively.
Three (12%) of the 26 cancer medicines reported both PFS and
OS gains that would clearly be considered clinically meaningful,
meeting the upper targets recommended by the ASCO-CRC (cetux-
imab for squamous cell head and neck cancer, pertuzumab for
HER2-positive metastatic [stage IV] breast cancer in combination
with trastuzumab, and trametinib for unresectable stage III or
stage IV malignant melanoma in combination with dabrafenib).
The majority of the medicines, 17 of 26 (65%), failed to meet the
lowest clinically meaningful target for either PFS or OS gains, with
seven medicines (27%) failing to meet the lowest target for both
PFS and OS. Five (19%) of the 26 medicines provided either no
health gain at all, or worse, health losses (a negative PFS or OS
gain) when compared with the New Zealand–funded alternative.
Thirteen of the 26 medicines included in the ﬁnal analysis set
were funded for one of more of the speciﬁc cancer typesconsidered by the ASCO-CRC working groups (breast, colon, lung,
or pancreas). Figs. 5A and 5B outline the PFS and OS gains for these
medicines relative to the speciﬁc targets recommended for each of
the four cancer types (as outlined in Table 1). Only one of these 13
medicines (8%) exceeded the recommended upper target for
clinically meaningful gains for both PFS and OS (pertuzumab for
breast cancer), with the majority of the medicines, 10 of 13 (77%),
failing to meet the lower minimum clinically meaningful targets
for PFS or OS gains.
We also undertook an analysis of the correlation between PFS
and OS gains for the 21 cancer medicines for 27 indications that
had clinical trial data reported for both PFS and OS gains.
Fig. 6 plots the PFS and OS gains for the 27 indications (for 21
medicines) identiﬁed. Fig. 7 superimposes OS changes (gains or
losses) beyond PFS gains. Linear correlation between PFS and OS
gains was low, with a correlation coefﬁcient of 43%, and many (15
of 27) medicine/indications had OS gains that were different from
PFS gains by more than 71 month. This suggests, in this sample of
21 cancer medicines funded in one country and not another, that
the extent of PFS gain is not a strong predictor of commensurate
gain in OS.4. Discussion
Our work describes the population health gains that may be
foregone due to differences in public funding of cancer medicines
between New Zealand and Australia. Such an analysis is possible
within cancer, where the health beneﬁts of new medicines are
consistently supported by clinical trials that report standard
progression-free survival and overall survival health outcome
measures. Formal comparisons of the health beneﬁts of treatments
in or across other disease settings typically require more complex
Table 2
Cancer medicines identiﬁed for analysis.
# Medicine name Summary of indication(s) funded in
Australia
Clinical trial name [source] - trial
description
Comparator treatment
1 Raltitrexed Advanced colorectal cancer Trial 003 [30] - randomized, open
label, phase 3
Fluorouracil and leucovorin
2 Pemetrexed Mesothelioma in combination with
cisplatin
EMPHACIS [31]- randomized,
single-blind, phase 3
Cisplatin
Locally advanced or metastatic non-small
cell lung cancer (NSCLC) following prior
platinum based chemotherapy
Hanna et al [32]- randomized,
open label, phase 3
Docetaxel
3 Vinorelbine (capsule) Locally advanced or metastatic non-small
cell lung cancer (NSCLC)
Trial 97 CA 205 [33] -
randomized, open label,
phase 2
IV vinorelbine
Advanced breast cancer following failure
of standard prior therapy including an
anthracycline
Trial CA221 [34] - randomized,
open label, phase 2
IV vinorelbine
4 Nano-particle albumin–bound
paclitaxel
Metastatic breast cancer Trial CA012-0 [35]- randomized,
open label, phase 3
Paclitaxel
Stage IV (metastatic) adenocarcinoma of
the pancreas in combination with
gemcitabine
MPACT [36] – randomized open
label, phase 3
Gemcitabine
5 Cabazitaxel Castration-resistant metastatic prostate
cancer; previously failed treatment with
docetaxel due to resistance or
intolerance
TROPIC [37] – randomized, open
label, phase 3
Mitoxantrone
6 Pegylated liposomal doxorubicin
hydrochlorided
Metastatic breast cancer; previously failed
treatment which included capecitabine
and a taxane due to resistance or
intolerance
Study I97-328 [38] – randomized,
open label, phase 3
Doxorubicin
Advanced epithelial ovarian cancer after a
failed ﬁrst-line platinum-based
chemotherapy regimen
Gordon et al [39] - randomized,
open label, phase 3
Topotecan
7 Panitumumab RAS wild-type metastatic colorectal
cancer in combination with ﬁrst line
chemotherapy, or after having failed to
respond to ﬁrst-line chemotherapy
PRIME study 20050203 [40] –
randomized, open label,
phase 3
FOLFOX
8 Cetuximab RAS wild-type metastatic colorectal
cancer in combination with ﬁrst line
chemotherapy, or after having failed to
respond to ﬁrst-line chemotherapy
CRYSTAL study (EMR 62 202-013)
[41]- randomized, open label,
phase 3
FOLFIRI
Stage III, Iva, or IVb squamous cell cancer
of the larynx, oropharynx or
hypopharynx intolerant or
contraindicated to cisplatin, in
combination with radiation therapy
EMR 62 202-006 [42] -
randomized, open label,
phase 3
Radiation therapy
9 Ipilimumab Unresectable stage III or stage IV
malignant melanoma
CA184-024 [43]- randomized,
double-blind placebo-
controlled, phase 3
Dacarbazine
10 Bevacizumab Metastatic colorectal cancer in
combination with ﬁrst-line
chemotherapy
NO16966 [44] - randomized,
double-blind placebo-
controlled, phase 3
FOLFOX-4 or XELOX
Stage IIIB, IIIC, or stage IV epithelial
ovarian, fallopian tube or primary
peritoneal cancer in combination with
platinum-based chemotherapy
GOG-0218 [45] - randomized,
double-blind placebo-
controlled, phase 3
Carboplatin with paclitaxel
11 Dabrafenib BRAFV600 mutation positive unresectable
stage III or stage IV malignant
melanoma
BREAK-3 [46]- randomized, open
label, phase 3
Dacarbazine
12 Sorafenib Advanced hepatocellular carcinoma SHARP Study 100554 [47] -
randomized, double-blind
placebo-controlled , phase 3
Placebo
Stage IV clear cell variant renal cell
carcinoma with progressive disease
following ﬁrst-line treatment with a
tyrosine kinase inhibitor
TARGET Study 11213 [48]-
randomized, double-blind
placebo-controlled , phase 3
Placebo
13 Eribulin Locally advanced or metastatic breast
cancer following failure of at least
2 prior chemotherapeutic regimens
EMBRACE study 305 [49] -
randomized, open label,
phase 3
Treatment of physician’s choice
14 Topotecan Advanced metastatic ovarian cancer after
failure of prior therapy that includes a
platinum compound
Randomised, open label, phase 3
[50]
Paclitaxel
15 Toremifene No restriction on funding—indicated for
hormone-dependent metastatic breast
cancer in postmenopausal patients
Study 5/044 [51] - randomized,
open label, phase 2
Tamoxifen
16 Enzalutamide Castration-resistant metastatic carcinoma
of the prostate unsuitable for, or having
failed treatment with, docetaxel due to
resistance or intolerance
CRPC2 (AFFIRM) study [52] -
randomized, double-blind
placebo-controlled , phase 3
Placebo
J. Evans et al. / Seminars in Oncology 43 (2016) 625–637 629
Table 2 (continued )
# Medicine name Summary of indication(s) funded in
Australia
Clinical trial name [source] - trial
description
Comparator treatment
17 Pertuzumab Metastatic (stage IV) HER2-positive breast
cancer in combination with
trastuzumab and a taxane
CLEOPATRA [53]- randomized,
open label, phase 3
Trastuzumab plus placebo
18 Trastuzumab emtansine Metastatic (stage IV) HER2-positive breast
cancer following pertuzumab and/or
trastuzumab treatment failure
EMILIA [54] - randomized, open
label, phase 3
Lapatinib plus capecitabine
19 Crizotinib ALK-mutation positive stage IIIB (locally
advanced) or stage IV (metastatic) non-
small cell lung cancer
Study 1007 [55] - randomized,
open label, phase 3
Pemetrexed or docetaxel
20 Pomalidomide Multiple myeloma ineligible for stem cell
transplant and having failed prior
lenalidomide and bortezomib
Study CC-4047-MM-003 [56]-
randomized, open label,
phase 3
High dose dexamethasone
21 Ofatumumab CD20þ chronic lymphocytic leukemia in
combination with chlorambucil in
patients who have non-progressed
disease and are inappropriate for
ﬂudarabine-based chemotherapy
COMPLEMENT 1 Study
OMB110911 [57] - randomized,
open label, phase 3
Chlorambucil
22 Obinutuzumab CD20þ chronic lymphocytic leukemia
together with chlorambucil, previously
untreated and inappropriate for
ﬂudarabine-based chemotherapy
BO21004/CLL11 [58] -
randomized, open label,
phase 3
Chlorambucil
23 Carmustine implant Suspected or conﬁrmed glioblastoma
multiforme at time of surgery
Westphal et al [59] - randomized,
double-blind placebo-
controlled , phase 3
Placebo implant
24 Trametinib Unresectable stage III or stage IV
malignant melanoma in combination
with dabrafenib
MEK115306 (COMBI-d) [60]-
randomized, double-blind
placebo-controlled , phase 3
Dabrafenib (indirect
comparison with dacarbazine
undertaken using BREAK-3
[46])
25 Pembrolizumab Unresectable stage III or stage IV
malignant melanoma negative for a
BRAF V600 mutation, or positive for a
BRAF V600 mutation and must have
progressed following treatment with a
BRAF inhibitor unless contraindicated or
not tolerated
KEYNOTE 006 [61] - randomized,
open label, phase 3
Ipilimumab (indirect
comparison with dacarbazine
undertaken using CA184-024
[43])
26 Axitinib Stage IV clear cell variant renal cell
carcinoma following ﬁrst-line treatment
with a tyrosine kinase inhibitor
AXIS [62]- randomized, open
label, phase 3
Sorafenib (indirect comparison
with placebo undertaken
using SHARP Study 100554
[47])
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(QALYs) extrapolated from surrogate outcomes over shorter
timeframes.
We used the ASCO-CRC recommendations for this analysis as
these offer internationally authoritative targets for clinically mean-
ingful health gain developed with input from a wide range of
stakeholders, including oncologists and patients. The ASCO-CRC
approach is easy to understand and technically simple, without the
requirement to model assumptions in the absence of direct
evidence of survival gains. Other cancer speciﬁc health beneﬁt
scales are available such as the recently published ASCO Value
Framework (ASCO-VF) [20] and European Society for Medical
Oncology Magnitude of Clinical Beneﬁt Scale (ESMO-MCBS) [21].
Both have similarities to the ASCO-CRC targets, the main difference
being that the ASCO-VF and the ESMO-MCBS derive a score that
can be used to consider the relative magnitude of health beneﬁt
that can be anticipated from new cancer medicines, whereas the
ASCO-CRC work derived absolute targets for deﬁning what would,
or would not, be considered a clinically meaningful beneﬁt. Given
that both the ASCO-CRC targets and the ACSO-VF and ESMO-MCBS
use the progression-free survival and overall survival gains
reported from clinical trials, we expect that the conclusions
reached using the different methodologies would be similar.
Indeed the ESMO-MCBS publication [21] notes that the ASCO-
CRC recommended targets for overall survival beneﬁts correlate
very closely with the thresholds for ESMO-MCBS score of 4–5, and
the recommended targets for PFS correlate closely with thethresholds for ESMO-MCBS score of 3–4, the highest attainable
when the primary outcome is PFS. We further note there have
been recent concerns published regarding the ASCO-VF [63-66],
culminating in recent changes to it [67].
While this analysis shows that, as at April 30, 2016, New
Zealand funded fewer cancer medicines than Australia (102 v
124), it also shows that New Zealand has avoided funding a large
number of cancer medicines that offer little or no clinically
meaningful beneﬁt for patients relative to currently funded
options in New Zealand, and in some cases it has avoided funding
medicines that deliver health losses.
Of the cancer medicines funded in Australia but not in New
Zealand, only three medicines clearly exceed ASCO-CRC’s recom-
mended upper target for clinically meaningful gains in both PFS
and OS. PHARMAC continues to assess all three of these medicines
for funding, relative to other medicines for other diseases that also
wait funding. At the time of writing, these medicines are a
considered by PHARMAC to be lower priority for funding relative
to other medicines for other diseases also waiting for funding, and
thus no positive funding decision has been made for them.
PHARMAC has no deﬁnitive timeframe for when its funding
decisions must be made; this is because the relative priority of
the various medicine funding options may change over time. The
relative priority of any one medicine is dependent on the mix of
other medicines being assessed at any one time; details like the
amount of funding available, success of negotiations with suppliers
or new clinical data can also change the relative priorities of one
Table 3
Clinical trial reported outcomes and calculated PFS and OS gains, relative to the New Zealand–funded comparator.
# Medicine name Abbreviated indication
funded in Australia
Reported PFS (mo) Reported OS (mo)
Trial subject Comparator Marginal gain Trial subject Comparator Marginal gain
1 Raltitrexed Colorectal* 4.8 3.6 1.2 10.1 10.2 -0.1
2 Pemetrexed Mesothelioma* 6.1 3.9 2.2 13.3 10.0 3.3
NSCLC 2.9 2.9 0.0 8.3 7.9 0.4
3 Vinorelbine (cap) NSCLC 3.3 2.1 1.2 9.4 7.9 1.5
Breast n.r. n.r. n.r. 9.4 10.2 -0.8
4 Nanoparticle albumin bound paclitaxel Breast 5.2 3.8 1.4 15.0 12.7 2.3
Pancreatic 5.5 3.7 1.8 8.5 6.7 1.8
5 Cabazitaxel Prostate 2.8 1.4 1.4 15.1 12.7 2.4
6 Pegylated liposomal doxorubicin
hydrochloride
Breast 6.9 7.8 -0.9 21.0 22.0 -1.0
Ovarian 4.1 4.2 -0.1 14.5 13.8 0.7
7 Panitumumab Colorectal 10.8 7.9 2.9 27.4 20.7 6.7
8 Cetuximab Colorectal 11.4 8.4 3.0 28.4 20.2 8.2
Head and neck* 24.4 14.9 9.5 49.0 29.3 19.7
9 Ipilimumab Melanoma 2.7 2.5 0.2 11.2 9.1 2.1
10 Bevacizumab Colorectal 9.4 8.0 1.4 21.2 19.9 1.3
Ovarian 19.1 13.1 6.0 43.8 40.6 3.2
11 Dabrafenib Melanoma 6.9 2.7 4.2 n.r n.r n.r
12 Sorafenib Hepatocellular 5.5 2.8 2.7 10.7 7.9 2.8
Renal 5.6 2.8 2.8 19.3 15.9 3.4
13 Eribulin Breast 3.7 2.2 1.5 13.2 10.6 2.6
14 Topotecan Ovarian* 6.5 5.5 1.0 15.8 13.3 2.5
15 Toremifene Breast* 5.6 5.8 -0.2 38.2 31.7 6.5
16 Enzalutamide Prostate 8.3 2.9 5.4 18.4 13.6 4.8
17 Pertuzumab Breast 18.5 12.4 6.1 56.5 40.8 15.7
18 Trastuzumab emtansine Breast 9.6 6.4 3.2 30.9 25.2 5.8
19 Crizotinib NSCLC 7.7 3.0 4.7 20.3 22.8 -2.5
20 Pomalidomide Multiple myeloma 3.7 1.9 1.8 12.8 8.1 4.7
21 Ofatumumab CLL 22.4 13.1 9.3 n.r n.r n.r
22 Obinutuzumab CLL 27.2 11.1 16.1 n.r n.r n.r
23 Carmustine implant Glioblastoma n.r n.r n.r 13.9 11.6 2.3
24 Trametinib Melanoma 10.9 3.0 7.9 16.6 9.0 7.6
25 Pembrolizumab Melanoma 4.1 2.8 1.3 n.r n.r n.r
26 Axitinib Renal 9.5 2.8 6.7 19.5 15.9 3.6
Median gain 2.2 2.6
n.r. ¼ data not reported; data displayed in italics has been derived from indirect comparison analysis using Bucher method.
n Indications that had clinical trial data that presented time-to-progression instead of PFS gains.
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has yet been made for these medicines, if in the future they do
become prioritised above other medicines for other diseases and
funding is available they would be funded. Most of the other
cancer medicines identiﬁed in this analysis are also under active
consideration by PHARMAC [68].
We undertook this work in response to reports ascribing
international differences in population health outcomes to simple
counts of absolute numbers of publicly funded medicines [2-5].
We have found that simply having more funded medicines
numerically does not necessarily lead to meaningful health gains.
One limitation of our work, however, is that we excluded medi-
cines that have at least one funded indication in New Zealand. The
funded indications for these medicines may not be identical across
Australia and New Zealand. There remains scope for further
research to explore the health consequences of these differences.
We note that in general New Zealand has fewer funding restric-
tions on its cancer medicines than Australia (in New Zealand,
about 80% of publicly-funded cancer medicines are open listed (ie,
funded for any use) compared with 10% in Australia).
It is also noteworthy that three of the medicines included in the
analysis identiﬁed as not being funded in New Zealand do have
alternative presentations of the active ingredient(s) that are
funded; New Zealand funds an injectable formulation of vinor-
elbine, whereas Australia funds both injectable and capsule
formulations. Similarly, while New Zealand funds both paclitaxel
and doxorubicin, Australia funds paclitaxel and nano-particle–
bound paclitaxel (nab-paclitaxel) and doxorubicin and pegylatedliposomal doxorubicin (PLDH). In addition, one of the medicines
included in the analysis (topotecan), has been previously funded in
New Zealand but was subsequently discontinued by the pharma-
ceutical suppliers in New Zealand for commercial reasons unre-
lated to PHARMAC’s activities.
Where there is some evidence of clinically meaningful beneﬁt
for a new medicine, PHARMAC must deploy its funding resources
across all diseases to obtain the best health outcomes for the
population, guided by its Factors for Consideration. We estimate
the cost to the Australian government of funding all of the 26
cancer medicines for the 33 indications identiﬁed in this analysis
to be approximately AUD $600 million per annum [69]. In New
Zealand terms, funding all of these medicines to achieve funding
parity with Australia would cost approximately NZD $130 million
per annum (using 0.9145 as the average AUD/NZD exchange rate
over past 12 months and NZ’s population being 19.3% that of
Australia’s) [70]. This is more than New Zealand currently spends
on all of its 102 funded cancer medicines for its population of
around 4.7 million people.
Based on health gains alone, a case for funding most of
medicines we identiﬁed (17 of 26) cannot be made. These
medicines failed to meet even the lowest clinically meaningful
target for either PFS or OS gains, compared with currently
funded medicines in New Zealand; ﬁve provide worse health
outcomes, with their clinical trials evidence showing acceler-
ated time to disease progression or death. The estimated cost of
funding these ﬁve medicines in New Zealand would be approx-
imately $10 million per year based on current Australian prices
Fig. 3. PFS gains foregone for medicines funded in Australia but not in New Zealand. Medicines marked with an asterisk (*) have been assessed by PHARMAC and either
remain under assessment for funding or have been declined by PHARMAC, http://www.pharmac.govt.nz/patients/ApplicationTracker. Green bars represent the gains that
met or exceeded the ASCO-CRC overall upper target for clinically meaningful PFS health gain (PFS gain of 5 months or more), orange striped bars represent gains that fell
below the upper target but met or exceeded the lower target (Z3 months to o5 months), and red spotted bars those that fell below the lower target (o3 months).
Horizontal dashed lines represent the thresholds for the upper and lower targets of 5 months and 3 months, respectively.
J. Evans et al. / Seminars in Oncology 43 (2016) 625–637632and volumes, and the clinical trial evidence shows that they
would have a negative impact on New Zealand’s overall cancer
survival and disease progression outcomes compared with the
status quo.Fig. 4. OS gains foregone for medicines funded in Australia but not in New Zealand. M
remain under assessment for funding or have been declined by PHARMAC, http://www
met or exceeded the ASCO-CRC overall upper target for clinically meaningful OS health
below the upper target but met or exceeded the lower target (Z2.5 months to o6 moAlthough many new cancer treatments may meet the regula-
tory standards for marketing approval, ie, show statistically
signiﬁcant health gains in a clinical trial setting, the magnitude
of these gains are often small and in many cases cannot beedicines marked with an asterisk (*) have been assessed by PHARMAC and either
.pharmac.govt.nz/patients/ApplicationTracker. Green bars represent the gains that
gain (OS gain of 6 months or more), orange striped bars represent gains that fell
nths), and red spotted bars those that fell below the lower target (o2.5 months).
Fig. 5. (A) PFS gains and (B) OS gains foregone for breast, colon, lung, and pancreas medicines funded in Australia but not in New Zealand. Medicines marked with an asterisk
(*) have been assessed by PHARMAC and either remain under assessment for funding or have been declined by PHARMAC, http://www.pharmac.govt.nz/patients/
ApplicationTracker. Green bars represent the gains that met or exceeded the ASCO-CRC overall upper target for clinically meaningful PFS health gain, orange striped bars
represent gains that fell below the upper target but met or exceeded the lower target, and red spotted bars those that fell below the lower target. Horizontal dashed lines
represent the thresholds for the upper and lower targets for each cancer disease type—refer to Table 1 for details regarding PFS gain targets for individual cancer disease
types (breast, lung, colon, and pancreas).
J. Evans et al. / Seminars in Oncology 43 (2016) 625–637 633considered clinically meaningful for patients in terms of improving
the length or quality of life. Our work supports the ﬁndings of a
review of the 71 cancer medicines for solid cancers approved by
the US FDA in the 12 years between 2002 to 2014, which showed
overall progression-free and overall survival gains of only 2.5 and
2.1 months respectively, with only 42% meeting the targets set by
the ASCO-CRC for clinically meaningful gains [9].
Our analysis also demonstrates that gains in PFS do not confer a
commensurate gain in overall survival, with poor correlation
between the two outcomes (see Appendix B). As an example, in
our analysis, the median PFS gain for crizotinib for ALK-positive
non-small cell lung cancer was 4.7 months, yet the median OS gainwas 2.5 months worse than the comparator. Our ﬁndings support
the work of others conﬁrming that caution is needed when
interpreting the health beneﬁts for cancer treatments on the basis
of PFS gains alone [71,72]. There is also an increasing trend
towards using even earlier surrogate endpoints in cancer [10],
such as tumor response rates. Such endpoints enable companies to
bring their medicines to market sooner, often using accelerated
approval pathways; however, the evidence supporting the validity
of early endpoints as surrogates for cancer survival is limited [73].
A recent analysis of cancer medicines granted FDA approval on the
basis of surrogate endpoints between 2008 and 2012 showed that
of the 36 approved, only ﬁve were subsequently shown to improve
Fig. 6. Cancer medicines funded in Australia but not in New Zealand—correlation between gains for PFS and OS. Blue downward-sloping lines represent the lower and upper
targets for clinically-meaningful PFS and OS gains. The closer a medicine/indication’s result lies to the linear regression line, the closer is the medicine/indication’s OS gain to
its PFS gain. The further away from the vertical and horizontal axes, the greater the difference.
J. Evans et al. / Seminars in Oncology 43 (2016) 625–637634OS, with the majority either failing to improve survival or having
an unknown effect [74]. Others have argued that cancer medicines
in particular get an “easy ride” from regulators, through a mix of
methodological weaknesses in clinical trials, accelerated approval-9.0 -6.0 -3.0 0.0
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Fig. 7. Cancer medicines funded in Australia but not in New Zealand—gains in PFS, a
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the difference between the OS and PFS gains (ie, the extra OS gain, beyond PFS gain). Ne
being less than the PFS gain. Asterisks (*) denote clinical trial data that presented timepathways and reliance on early surrogate outcomes that are highly
variable in their ability to predict survival outcomes [10,75].
Health beneﬁts, in terms of PFS and OS gains, are only part of the
information taken into account by PHARMAC when making its cancer3.0 6.0 9.0 12.0 15.0 18.0
remental changes in OS (months)
xtra OS gain
* = Time-To-Progression instead of Progress-free Survival gains 
nd then extra (incremental) gains in OS (beyond the PFS changes). Notes: Close
niform, ie, the red bars would be roughly equal. The longer the red bar, the greater
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-to-progression instead of PFS gains.
J. Evans et al. / Seminars in Oncology 43 (2016) 625–637 635medicine funding decisions [76]. While our analysis here focusses on
PFS and OS gains, some medicines may provide other beneﬁts not
captured using these endpoints. For example, new treatments may be
better tolerated, easier to administer or free up health sector resources.
PHARMAC makes its decisions taking into account its Factors for
Consideration, which capture all such beneﬁts [23]. Notably, PHAR-
MACmust make its decisions within the funding available. This means
that all new funding applications are assessed relative to each other, so
that the value of investing in new cancer medicines can be compared
with possible investment in new medicines for other conditions such
as diabetes, asthma and infections.5. Conclusions
Our analysis shows that, while New Zealand funds fewer cancer
medicines than Australia, most of these additional medicines do
not deliver clinically meaningful health gains in terms of extending
time to disease progression or death for cancer patients. This
suggests that simply funding more cancer medicines to achieve
funding parity with Australia would likely not represent good
value for money in terms of delivering the best health outcomes
for New Zealanders. PHARMAC’s method for selective funding of
new medicines that demonstrate clear clinical beneﬁt and that are
cost-effective and affordable is a sensible approach, ensuring that
scarce health dollars are not directed towards medicines that are
unlikely to deliver clinically meaningful health gains to patients.Conﬂicts of interest
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